Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

4 Issues per year


IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854

Open Access
Online
ISSN
1846-9558
See all formats and pricing
More options …
Volume 57, Issue 1 (Mar 2007)

Issues

Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties

Yousef Javadzadeh
  • Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mohammad Siahi
  • Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Solmaz Asnaashari
  • Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ali Nokhodchi
  • Medway School of Pharmacy Central Ave., University of Kent and Greenwich, Chatham, Kent, ME4 4TB United Kingdom
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2007-02-28 | DOI: https://doi.org/10.2478/v10007-007-0008-6

Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties

The potential of liquisolid systems to improve the dissolution properties of a water-insoluble agent (indomethacin) was investigated. In this study, different formulations of liquisolid tablets using different co-solvents (non-volatile solvents) were prepared and the effect of aging on the dissolution behaviour of indomethacin liquisolid compacts was investigated. To evaluate any interaction between indomethacin and the other components in liquisolid formulations, X-ray powder diffraction (XPD) and differential scanning calorimetry (DSC) were used. Dissolution test was carried out at two different pH, 1.2 and 7.2, to simulate the stomach or intestine fluid, respectively. The results showed that liquisolid formulations exhibited significantly higher drug dissolution rates at pH 1.2 and 7.2 compared to compacts prepared by the direct compression technique. The enhanced rate of indomethacin dissolution from liquisolid tablets was probably due to an increase in wetting properties and surface area of drug particles available for dissolution. In order to investigate the effect of aging on the hardness and dissolution rate of liquisolid compacts, the formulations were stored at 25 °C/75% relative humidity for a period of 12 months. The results showed that aging had no significant effect on dissolution profiles of liquisolid tablets. Liquisolid compacts containing propylene glycol as vehicle produced higher dissolution rates in comparison with liquisolid compacts containing PEG 400 or Tween 80 of the same concentration. The DSC and XPD results showed no changes in crystallinity of the drug and interaction between indomethacin and excipients (Avicel and silica) during the process.

Keywords: indomethacin; liquisolid compacts; dissolution rate; aging; DSC; XPD

  • S. G. Kapsi and J. W. Ayres, Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, Int. J. Pharm. 229 (2001) 193-203.Google Scholar

  • A. J. Aguiar, A. J. Zelmer and A. W. Kinkel, Deagglomeration behavior of relatively insoluble benzoic acid and its sodium salt, J. Pharm. Sci. 56 (1967) 1243-1252.CrossrefGoogle Scholar

  • P. Finholt and S. Solvang, Dissolution kinetics of drugs in human gastric juice; the role of surface tension, J. Pharm. Sci. 57 (1968) 1322-1326.CrossrefGoogle Scholar

  • S. L. Lin, J. Menig and L. Lachman, Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water insoluble drugs, J. Pharm. Sci. 57 (1968) 2143-2146.CrossrefGoogle Scholar

  • S. Spireas and S. Sadu, Enhancement of prednisolone dissolution properties using liquisolid compacts, Int. J. Pharm. 166 (1998) 177-188.Google Scholar

  • S. Spireas, S. Sadu and R. Grover, In vitro release evaluation of hydrocortisone liquisolid tablets, J. Pharm. Sci. 87 (1998) 867-872.Google Scholar

  • S. Spireas, T. Wang and R. Grover, Effect of powder substrate on the dissolution properties of methchrothiazide liquisolid compacts, Drug Dev. Ind. Pharm. 25 (1999) 163-168.PubMedCrossrefGoogle Scholar

  • K. Y. Yang, R. Glemza and C. I. Jarowski, Effect of amorphous silicon dioxide on drug dissolution, J. Pharm. Sci. 68 (1979) 560-565.Google Scholar

  • C. Liao and C. I. Jarowski, Dissolution rates of corticoid solutions dispersed on silicas, J. Pharm. Sci. 73 (1984) 401-403.Google Scholar

  • A. Nokhodchi, Y. Javadzadeh, M. R. Siahi and M. Barzegar-Jalali, The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts, J. Pharm. Pharm. Sci. 8 (2005) 18-25.Google Scholar

  • United States Pharmacopocia 26, Natural Formulary 21, USP Convention, Rockville 2003.Google Scholar

  • P. Costa, An alternative method to the evaluation of similarity factor in dissolution testing, Int. J. Pharm. 220 (2001) 77-83.Google Scholar

  • P. Costa and J. M. S. Lobo, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133.CrossrefGoogle Scholar

  • K. A. Khan, Concept of dissolution efficiency,J. Pharm. Pharmacol. 27 (1975) 48-49.CrossrefGoogle Scholar

  • H. Abdou, Effect of the physicochemical properties of the drug on dissolution in Dissolution, Bioavailability and Bioequivalence (Ed. H. Abdou), Edison Mack Publishing Co., Easton, PA 1989, pp. 53-72.Google Scholar

  • N. Kaneniwa, M. Otsuka and T. Hayashi, Physicochemical characterization of indomethacin polymorphs and transformation kinetics in ethanol, Chem. Pharm. Bull. 33 (1985) 3447-3455.Google Scholar

  • H. Imaizumi, N. Nambu and T. Nagai, Stability of several physical properties of amorphous and crystalline forms of indomethacin, Chem. Pharm. Bull. 28 (1980) 2565-2569.CrossrefGoogle Scholar

  • L. Borka, Polymorphism of indomethacin. New modifications, their melting behavior and solubility, Acta Pharm. Suecica 11 (1974) 295-303.Google Scholar

  • M. Otsuka, F. Kato and Y. Matsuda, Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry, Analyst 126 (2001) 1578-1582.Google Scholar

  • M. Yoshioka, B.C. Hancock and G. Zografi, Crystallization of indomethacin from the amorphous state below and above its glass transition temperature, J. Pharm. Sci. 83 (1994) 1700-1705.Google Scholar

  • H. Imaizumi, N. Nambu and T. Nagai, Stabilization of amorphous state of indomethacin by solid dispersions in polyvinylpyrolidone, Chem. Pharm. Bull. 31 (1983) 2510-2512.CrossrefGoogle Scholar

About the article


Published Online: 2007-02-28

Published in Print: 2007-03-01


Citation Information: Acta Pharmaceutica, ISSN (Online) 1846-9558, ISSN (Print) 1330-0075, DOI: https://doi.org/10.2478/v10007-007-0008-6.

Export Citation

This content is open access.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
N.R. Jadhav, P.V. Irny, and U.S. Patil
Journal of Drug Delivery Science and Technology, 2017, Volume 38, Page 97
[2]
Nihal M. El-Mahdy El-Sayyad, Alia Badawi, Mohammed Effat Abdullah, and Nevine Shawky Abdelmalak
Bulletin of Faculty of Pharmacy, Cairo University, 2017, Volume 55, Number 1, Page 53
[3]
Mei Lu, Haonan Xing, Jingzheng Jiang, Xiao Chen, Tianzhi Yang, Dongkai Wang, and Pingtian Ding
Asian Journal of Pharmaceutical Sciences, 2017, Volume 12, Number 2, Page 115
[4]
Yousef Javadzadeh, Hesam Shariati, Elmira Movahhed-Danesh, and Ali Nokhodchi
Drug Development and Industrial Pharmacy, 2009, Volume 35, Number 2, Page 243
[5]
Leila Azharshekoufeh B., Javad Shokri, Khosro Adibkia, and Yousef Javadzadeh
Colloids and Surfaces B: Biointerfaces, 2015, Volume 136, Page 185
[6]
Ahmed S. Zidan, Bader M. Aljaeid, Mahmoud Mokhtar, and Tamer M. Shehata
Pharmaceutical Development and Technology, 2015, Volume 20, Number 6, Page 652
[7]
Khosro Adibkia, Javad Shokri, Mohammad Barzegar-Jalali, Mohammad Solduzian, and Yousef Javadzadeh
Colloids and Surfaces B: Biointerfaces, 2014, Volume 113, Page 10
[8]
Amal Ali Elkordy, Umesh Bhangale, Niraj Murle, and Moataz Fathy Zarara
Powder Technology, 2013, Volume 246, Page 182
[9]
Naveen Chella, Nalini Shastri, and Rama Rao Tadikonda
Acta Pharmaceutica Sinica B, 2012, Volume 2, Number 5, Page 502
[10]
Ambedkar Sunil Songa, Venkata Srikanth Meka, Sreenivasa Rao Nali, and Venkata Ramana Murthy Kolapalli
Drug Development and Industrial Pharmacy, 2013, Volume 39, Number 3, Page 447
[11]
Ngiik Tiong and Amal A. Elkordy
European Journal of Pharmaceutics and Biopharmaceutics, 2009, Volume 73, Number 3, Page 373
[12]
Ali Nokhodchi, Christina M Hentzschel, and Claudia S Leopold
Expert Opinion on Drug Delivery, 2011, Volume 8, Number 2, Page 191

Comments (0)

Please log in or register to comment.
Log in